{Reference Type}: Journal Article
{Title}: Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.
{Author}: Massa H;Nagar AM;Vergados A;Dadoukis P;Patra S;Panos GD;
{Journal}: J Int Med Res
{Volume}: 47
{Issue}: 1
{Year}: Jan 2019
{Factor}: 1.573
{DOI}: 10.1177/0300060518816884
{Abstract}: Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN®. The results of the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) studies are also presented together with the results of real-world studies to support the clinical use of ILUVIEN® in achieving efficient resolution of DMO and improving vision and macular anatomy in this challenging group of patients.